Provided by Tiger Fintech (Singapore) Pte. Ltd.

Relmada Therapeutics, Inc.

0.2960
+0.00130.44%
Post-market: 0.2846-0.0114-3.85%18:13 EDT
Volume:146.47K
Turnover:43.14K
Market Cap:8.93M
PE:-0.10
High:0.3011
Open:0.2927
Low:0.2900
Close:0.2947
Loading ...

Relmada Therapeutics Inc expected to post a loss of 70 cents a share - Earnings Preview

Reuters
·
15 Mar

Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial

TipRanks
·
14 Mar

Asarina Pharma Ab (Publ) - Signs Asset Purchase Agreement With Relmada Therapeutics

THOMSON REUTERS
·
07 Feb

Relmada Therapeutics acquires Sepranolone from Asarina Pharma

TIPRANKS
·
06 Feb

Relmada Therapeutics Inc - Acquires Sepranolone for EUR 3 Million

THOMSON REUTERS
·
06 Feb

Relmada Therapeutics Acquires Potential Therapy for Tourette Syndrome From Asarina Pharma Ab

THOMSON REUTERS
·
06 Feb

BRIEF-Relmada Therapeutics Acquires Potential Therapy For Tourette Syndrome From Asarina Pharma AB

Reuters
·
06 Feb

Relmada Therapeutics Acquires Potential Therapy for Tourette Syndrome From Asarina Pharma Ab

THOMSON REUTERS
·
06 Feb

Relmada Therapeutics: Purchases Sepranolone, for Treatment of Tourette Syndrome and Other Compulsion-Related Conditions From Asarina Pharma Ab

THOMSON REUTERS
·
06 Feb

BUZZ-Relmada Therapeutics explores strategic options; shares up

Reuters
·
09 Dec 2024

Relmada Therapeutics Shares up 7% After Co Says It Will Explore Strategic Alternatives Including a Sale

THOMSON REUTERS
·
09 Dec 2024

Relmada Therapeutics Exploring Sale After Lead Program Failure

Dow Jones
·
09 Dec 2024

Relmada discontinues late-stage trials for depression drug, explores sale

Reuters
·
09 Dec 2024

BRIEF-Relmada Therapeutics To Discontinue The Reliance Ii And Relight Phase 3 Studies Of Rel-1017

Reuters
·
09 Dec 2024

Relmada Therapeutics to Discontinue the Reliance Ii and Relight Phase 3 Studies of Rel-1017

THOMSON REUTERS
·
09 Dec 2024

Relmada Therapeutics Inc: Will Continue to Advance Phase 1 Study of Rel-P11, an Investigational Agent for Treatment of Metabolic Disease

THOMSON REUTERS
·
09 Dec 2024